CRISPR Breakthrough for Rare Disease: Dr. Martha Boeckenfeld Highlights a New Era in Gene Therapy

In a recent LinkedIn post, Dr. Martha Boeckenfeld highlights a groundbreaking case of personalized gene editing, showcasing the potential of rapid, targeted therapies for rare diseases. Dr. Boeckenfeld draws attention to the remarkable story of KJ Muldoon, an infant diagnosed with the extremely rare CPS1 deficiency, a metabolic disorder affecting his liver’s ability to clear ammonia.

As Dr. Boeckenfeld notes, the severity of KJ’s condition was stark: “His liver couldn’t clear ammonia. He had months to live.” The post details how CPS1 deficiency is life-threatening, with over 50% of affected infants not surviving past age two without a liver transplant.

A Six-Month Leap in Gene Therapy Development

Dr. Boeckenfeld emphasizes the unprecedented speed at which researchers at Children’s Hospital of Philadelphia and Penn Medicine developed a solution for KJ. Instead of the typical years-long process for drug development, a custom CRISPR-based therapy, tailored to KJ’s specific mutation, was engineered in just six months.

“They built a custom CRISPR-based therapy — designed for KJ’s exact mutation — in six months. Not years.”

This rapid development culminated in the infusion of the therapy in February 2025. Dr. Boeckenfeld shares the transformative results, which defied the grim prognosis.

Transformative Patient Outcomes

The impact of the personalized gene therapy on KJ’s health has been profound, as detailed by Dr. Boeckenfeld. The post highlights several key improvements:

• Doubled dietary protein intake
• Halved reliance on nitrogen-scavenger medications
• Stable ammonia levels, even during typically crisis-inducing viral illnesses
• Weight gain, moving from the 9th to the 26th percentile
• Avoidance of a liver transplant

According to Dr. Boeckenfeld, KJ is now thriving as a toddler. This single-patient success story, Dr. Boeckenfeld argues, serves as a powerful proof-of-concept for personalized gene editing.

“One patient proves personalized gene editing can work.”

Scaling the Impact: From One Patient to Many

Dr. Boeckenfeld looks beyond KJ’s individual case to envision the broader implications for rare disease treatment. The post suggests that treating ten more CPS1 patients will yield crucial data on treatment durability and efficacy. This iterative approach, Dr. Boeckenfeld posits, could pave the way for similar gene-editing strategies to be applied to hundreds of other rare liver disorders.

Redefining ‘Untreatable’

The overarching message from Dr. Boeckenfeld’s post is a hopeful redefinition of what constitutes an “untreatable” condition. By focusing on clear targets and demonstrating a willingness to accelerate development timelines, the medical community can move away from questioning the possibility of personalization and towards implementing it as a standard practice.

“At scale, medicine stops asking ‘can we personalize this?’ and starts asking ‘why didn’t we sooner?'”

Dr. Boeckenfeld concludes by posing a critical question about the vast potential yet to be unlocked: “What other ‘untreatable’ conditions are six months of focused work away from an answer?” This perspective underscores the urgency and excitement surrounding the advancements in gene therapy, driven by innovation and a patient-centric approach.